–1– I. 背景 誠如本公司日期為2025年5月30日的公佈所披露，本公司於2025年5月23日接獲聯交 所發出的復牌指引，據此，本公司須就各項審計問題進行適當的獨立法證調查、評 估對本公司業務營運及財務狀況的影響、公佈調查結果並採取適當的補救行動。 誠如本公司日期為2025年4月22日及2025年6月30日的公告所披露，董事會決議成立 調查委員會，調查委員會已聘請獨立調查公司開展獨立調查。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號：6667） 內幕消息 獨立法證調查的主要結果 及 繼續暫停買賣 本公告乃由美因基因有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯 合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條以及香港法 例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 美因基因有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06667 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 ...

第 1 頁 共 10 頁 v 1.1.1 證券代號 (如上市) 06667 說明 法定/註冊股份數目 面值 法定/註冊股本 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 美因基因有限公司 | | | | | | 呈交日期: | 2025年10月2日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 增加 / 減少 (-) | | | | USD | | | --- | --- | --- | --- | --- | --- | | 上月底結存 本月底結存 | 500,000,000 500,000,000 | USD USD | 0.0001 0.0001 | USD USD | 50,000 50,000 | 本月底法 ...

此外，公司股份继续暂停买卖。 格隆汇9月30日丨美因基因(06667.HK)公告。根据上市规则第13.48(1)条，公司须于2025年9月30日或之 前，即财政期间结束日期后三个月内寄发截至2025年6月30日止六个月的中期报告予其股东。由于该等 公告所载事项，截至公告日期，刊发2024年全年业绩及寄发2024年年报仍有待落实。因此，预期无法根 据上市规则在规定时间内寄发2025年中期报告。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號：6667） 內幕消息 延遲刊發2025年中期報告 復牌進度季度更新 及 繼續暫停買賣 本公告乃由美因基因有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯 合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條以及香港法 例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上市規則）而作出。 本公司亦謹此知會其股東及潛在投資者本公司近期就符合復牌指引所採取行動的進展， 以及本集團業務營運的最新發展。 茲提述本公司日期為2025年4月1日、2025年4月22日、2025年4月30日、2025年5月5日、 2025年5月30日及2025年8月29日的公告（「該等公告」），內容有關（其中包括）(i)延遲刊 發2024年全年業績及2025年中期業績、 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 第 2 頁 共 10 頁 v 1.1.1 | 截至月份: | 2025年8月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 美因基因有限公司 | | | | | | 呈交日期: | 2025年9月2日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 06667 | 說明 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | 上月底結存 | | | 500,000,000 | USD | 0.0001 | USD | 50,000 | | 增加 / 減少 (-) | | | | | ...

內幕消息 延遲刊發2025年中期業績 及 繼續暫停買賣 本公告乃由美因基因有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯 合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條以及香港法 例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義見上市規則）而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mega Genomics Limited 美因基因有限公司* （於開曼群島註冊成立的有限公司） （股份代號：6667） 股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 美因基因有限公司 執行董事兼主席 茲提述本公司日期為2025年4月1日、2025年4月22日、2025年4月30日、2025年5月5日及 2025年5月30日的公告（「該等公告」），內容有關（其中包括）(i)延遲刊發2024年全年業 績、(ii)押後董事會會議、(iii)延遲刊發2024年年報、(iv)建議更換 ...

Company Overview - As of June 30, 2024, Mega Genomics has conducted over 21 million genetic tests since its establishment in 2016, averaging over 400,000 tests per month in the first half of 2024[8]. - The company has developed 107 commercialized testing solutions for consumer genetic testing and cancer screening, with 90 of these services being independently developed[8]. - Mega Genomics is recognized as the largest consumer genetic testing platform in China based on cumulative testing volume as of December 31, 2021[8]. - The company offers a range of popular testing services, including brain health assessment, nutritional absorption capability assessment, Parkinson's disease risk assessment, and comprehensive cancer risk assessment[8]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through internal R&D and collaborations with third-party partners[8]. - The R&D strategy is market-oriented, focusing on expanding testing technology platforms and services based on industry trends and market demands[15]. - The company has a strong internal R&D team, with approximately 65% of its members holding master's degrees or higher from prestigious institutions[17]. - The company plans to enhance its research and development capabilities by recruiting more professionals and collaborating with renowned academic and medical institutions[30]. Product Development and Registration - The ApoE gene testing kit, utilizing blood nucleic acid non-extraction technology, is expected to be registered by the NMPA in the second half of 2024[11]. - The folate metabolism assessment kit aims to guide pregnant women in folate supplementation and has also been submitted for NMPA registration, expected in the second half of 2024[12]. - The Alzheimer's disease screening kit is based on plasma miRNA biomarkers and is in collaboration with multiple hospitals for clinical validation, with a registration expected by 2025[13]. - The colorectal cancer screening kit is utilizing plasma DNA methylation markers, with over 1,500 samples used for biomarker selection, and is expected to achieve registration by 2025[14]. - The gastric cancer screening kit is also based on plasma DNA methylation markers, with similar development and registration timelines as the colorectal cancer kit[14]. - The BRCA1/BRCA2 gene mutation testing kit has completed formulation development and established a database of tens of thousands of mutation sites[15]. - The company has received product registration certificates for fecal occult blood and transferrin testing kits, which are now in mass production[15]. - The company is in the process of IVD registration for several products, including the ApoE gene testing kit and colorectal cancer screening kit, which are currently in the registration phase[21]. Financial Performance - For the six months ended June 30, 2024, the company achieved total revenue of RMB 107.3 million, an increase of RMB 8.4 million or 8.5% compared to RMB 98.9 million for the same period in 2023[25]. - Revenue from consumer-grade genetic testing services and cancer screening services for the six months ended June 30, 2024, was RMB 104.4 million and RMB 2.9 million, respectively[25]. - Gross profit for the period was RMB 69,618 thousand, up 6.6% from RMB 65,299 thousand in the previous year[26]. - The gross margin decreased to 64.9%, down 1.1 percentage points from 66.0% in the prior year[26]. - Net profit for the six months was RMB 36,969 thousand, reflecting a 5.3% increase from RMB 35,117 thousand year-on-year[26]. - Revenue from consumer-grade genetic testing services reached RMB 1,044 million for the six months ended June 30, 2024, representing an 83.2% year-over-year increase due to diversified sales channels and product optimization[36]. - Cancer screening services revenue was RMB 29 million for the same period, a 93.1% year-over-year decline attributed to price strategy adjustments and product structure optimization[36]. Operational Efficiency - The company has established partnerships with nearly 1,900 healthcare institutions across over 340 cities in China, with health check centers accounting for approximately 52% of its institutional clients[24]. - The company has developed a comprehensive technology platform that includes multiple testing technologies, enabling it to process up to 50,000 samples daily in its independent testing laboratory[22]. - The company has implemented a lean management approach to continuously optimize its personnel structure and improve operational efficiency[24]. Cash Flow and Financial Position - Net cash generated from operating activities was RMB 150 million, driven by improved collection of accounts receivable[50]. - The company's cash and cash equivalents decreased by 1.8% from RMB 5,183 million as of December 31, 2023, to RMB 5,089 million as of June 30, 2024[50]. - The company's debt-to-asset ratio as of June 30, 2024, was 20.4%, an increase of 1.4 percentage points from 19.0% on December 31, 2023[54]. - The company reported a decrease in trade receivables of RMB 31,822,000 during the reporting period, compared to an increase of RMB 21,347,000 in the same period of 2023[99]. - The company’s total liabilities decreased from RMB 273,169,000 as of December 31, 2023, to RMB 273,169,000 as of June 30, 2024, indicating stability in its financial position[101]. Shareholder Information - The company granted a total of 27,272,000 restricted share units during the reporting period[72]. - The company reported that 9.31% of its shares are held by Dr. Yu Rong through controlled entities, totaling 21,995,135 shares[79]. - Ms. Guo Meiling holds a total of 22,000,000 shares through controlled entities, representing 9.31% of the company's shares[79]. - The company has appointed a new company secretary, Mr. Wu Jiazh, effective June 28, 2024[78]. - The company’s CEO position was temporarily filled by Ms. Jiang Jing following the departure of Mr. Huang Yufeng on January 17, 2024[78]. Compliance and Governance - The company has maintained compliance with corporate governance codes and standards throughout the reporting period[90]. - The group operates a single reportable operating segment, monitoring overall performance without service grouping[104]. - The group has maintained its classification of current and non-current liabilities after reassessing terms and conditions as of January 1, 2024, with no impact on financial position[102].

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 107,291,000, representing an 8.5% increase compared to RMB 98,879,000 in the same period of 2023[2] - Net profit for the six months ended June 30, 2024, was RMB 36,969,000, reflecting a 5.3% increase from RMB 35,117,000 in the same period of 2023[2] - Gross profit for the period was RMB 69,618,000, with a gross margin of 64.9%, down from 66.0% in the previous year[2] - The company reported a gross margin of 64.9% and a net profit margin of 34.5% for the six months ended June 30, 2024, compared to 66.0% and 35.5% respectively for the same period in 2023[49] - The group reported a pre-tax profit of RMB 37,673,000 for the six months ended June 30, 2024, compared to RMB 33,580,000 for the same period in 2023, indicating a growth of 12.4%[68] Revenue Breakdown - Consumer-grade genetic testing services revenue increased by 83.2% to RMB 104,419,000 from RMB 57,011,000 year-over-year[2] - Revenue from consumer-grade genetic testing services reached RMB 104.4 million, a significant increase of 83.2% year-on-year, while cancer screening services generated RMB 2.9 million, reflecting a decrease of 93.1%[22] - Revenue from cancer screening services dropped to RMB 2.9 million, a decrease of 93.1% year-over-year, due to adjustments in pricing strategy and product structure[33] Product Development and Innovation - The company has developed 107 commercialized testing solutions, with 90 of them being self-developed services[7] - The company is currently developing eight in-vitro diagnostic (IVD) products, including three consumer-grade genetic testing kits[9] - The ApoE gene testing kit, developed by the company, is expected to synergize with Alzheimer's screening products and has completed clinical trials[9] - The self-developed folate metabolism assessment kit has completed clinical trials and is expected to obtain registration certification in the second half of 2024[10] - The Alzheimer's disease screening kit is in collaboration with multiple hospitals, utilizing at least 1,500 samples, and aims to achieve registration certification by 2025[11] - The colorectal cancer screening kit has completed preliminary biomarker screening and is expected to achieve registration certification by 2025, with sensitivity and specificity greater than 90%[11] - The gastric cancer screening kit is also in development, with similar timelines and performance metrics as the colorectal cancer kit[12] - The BRCA1/BRCA2 gene mutation detection kit has established a database of tens of thousands of mutation sites and is in the later stages of development[12] Research and Development - The internal R&D team consists of approximately 65% members with master's degrees or higher from prestigious institutions[14] - The company aims to expand its R&D capabilities by recruiting more professionals and collaborating with renowned academic and medical institutions[27] - The company is in the process of developing new products, including Alzheimer's screening kits and BRCA1/BRCA2 gene mutation testing kits, to meet the growing domestic market demand[18] Operational Efficiency - The company has a high-throughput testing platform capable of processing 50,000 samples daily, providing cost-effective genetic testing solutions[19] - The company has a laboratory in Beijing with a total area of approximately 880 square meters, certified for various testing services and compliant with clinical use requirements[20] - The company plans to enhance its cancer screening product line and increase automation in production to lower costs and improve sensitivity and specificity of tests[26] - A new production laboratory is planned to improve regional coverage, reduce operational costs, and enhance customer experience through faster report turnaround times[28] Financial Position - Cash and cash equivalents decreased by 1.8% from RMB 518.3 million as of December 31, 2023, to RMB 508.9 million as of June 30, 2024[48] - Total current assets as of June 30, 2024, were RMB 710,936,000, compared to RMB 667,778,000 at the end of 2023, showing a growth of 6.5%[59] - Total liabilities increased to RMB 169,429,000 as of June 30, 2024, compared to RMB 151,715,000 at the end of 2023, indicating an increase of 11.7%[60] Shareholder Information - Basic and diluted earnings per share for the period were RMB 0.18, up from RMB 0.16 in the previous year, marking a 12.5% increase[58] - The group did not declare or pay any dividends during the reporting period, consistent with the previous period[71] - The company aims to enhance net asset value per share and earnings per share through the share repurchase program authorized at the 2024 annual general meeting[82] Compliance and Governance - The audit committee, consisting of three members, has been established to provide independent opinions on the effectiveness of financial reporting procedures, internal controls, and risk management systems[85] - The audit committee has reviewed the unaudited interim financial information for the six months ending June 30, 2024, and discussed matters related to auditing, internal controls, and financial reporting[86]

Financial Performance - For the fiscal year ending December 31, 2023, the company recorded a total gross profit of RMB 883 million, representing an 8.0% year-over-year increase[32]. - The gross profit margin for the company was 58.4% for the fiscal year ending December 31, 2023, with the cancer screening service gross margin at 72.1%, an increase of 0.2 percentage points year-over-year[33]. - The gross profit from consumer-grade genetic testing services was RMB 573 million, showing a significant year-over-year increase of 64.4% due to optimized product and service offerings[32]. - For the fiscal year ending December 31, 2023, the company reported revenue of RMB 151.3 million, a 3.8% increase from RMB 145.7 million in 2022[43]. - The company's gross profit for the same period was RMB 88.3 million, with a gross margin of 58.4%, compared to RMB 81.7 million and a gross margin of 56.1% in 2022[66]. - The net profit for the fiscal year was RMB 30.0 million, a significant turnaround from a net loss of RMB 17.6 million in 2022, representing an increase of RMB 47.6 million[52]. - The company reported a gross profit margin of 58.4% for 2023, up from 56.1% in 2022, and a net profit margin of 19.9%, compared to a net loss margin of 12.1% in the previous year[127]. Research and Development - The company plans to enhance its R&D capabilities by recruiting more professionals and collaborating with renowned domestic and international academic and medical institutions[37]. - The company achieved a 15% increase in R&D investment, totaling RMB 22.4 million, with 97 commercialized testing solutions developed during the reporting period[58]. - The company has developed a blood nucleic acid non-extraction technology that effectively saves testing costs and time, with clinical trials involving approximately 1,200 cases expected to complete by the second half of 2024[16]. - The company plans to develop two types of testing kits using qPCR and NGS technologies, with the NGS kit expected to include dozens to hundreds of biomarkers[48]. - The company plans to obtain registration certification for its folate metabolism assessment testing kit in the second half of 2024 after completing clinical trials and submitting for NMPA registration[83]. Sales and Market Strategy - The company collaborated with over 1,800 healthcare institutions across more than 340 cities in China, with health check centers accounting for approximately 54% of the total institutional clients[30]. - The company has established a sales team of over 100 people, expanding its sales network to cover over 340 cities in China[40]. - The company aims to enhance market penetration by collaborating with industry leaders and establishing industry standards through academic conferences and expert collaborations[53]. - Cancer screening service revenue decreased by 34.1% year-over-year to RMB 42.9 million due to adjustments in sales strategy[46]. - The average price for general consumer genetic testing services was RMB 36.4, with a testing volume of 2,973 thousand tests, compared to RMB 48.0 and 1,340 thousand tests in 2022[45]. Operational Efficiency - The company plans to build production laboratories to enhance regional coverage, improve reporting cycles, and reduce operational costs[38]. - The company's administrative expenses increased from RMB 42.9 million in the year ended December 31, 2022, to RMB 44.5 million in 2023, mainly due to increased R&D personnel and related expenditures[94]. - The company's sales and distribution expenses decreased from RMB 34.9 million in the year ended December 31, 2022, to RMB 30.7 million in 2023, reflecting adjustments in sales strategies[93]. - The company's cash and cash equivalents increased by 29.6% from RMB 399.8 million as of December 31, 2022, to RMB 518.3 million as of December 31, 2023[74]. - The net cash generated from operating activities during the reporting period was RMB 163.7 million, significantly improving from a net cash used of RMB 6.9 million in the previous year[101]. Management and Governance - The company has a strong management team with extensive experience in healthcare and business management, enhancing its operational capabilities[184]. - The company has established a robust governance structure with independent directors overseeing strategic decisions[175]. - The management team is focused on leveraging their diverse backgrounds to drive the company's growth and operational efficiency[176]. - The company has undergone significant leadership changes, with Mr. Huang's tenure as a director from December 2020 to January 16, 2024[190]. - Ms. Jiang, the Chief Financial Officer since November 2020, has around 21 years of experience in financial management and will assume CEO responsibilities starting January 17, 2024[169]. Future Outlook - The company plans to utilize the net proceeds from its global offering for various purposes, including sales and marketing (30%), R&D (25%), and operational funding (10%) by June 30, 2025[120]. - The company aims to expand its market presence and enhance its service offerings through strategic planning and investor relations[164]. - The financial report indicates that the company is committed to transparency in its financial activities and will announce any changes in the intended use of proceeds[178]. - The company has no significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the year ended December 31, 2023[130]. - The company has no major events after December 31, 2023, that could significantly impact its operations and financial performance[135].